Compile Data Set for Download or QSAR
maximum 50k data
Found 313 with Last Name = 'furuya' and Initial = 't'
LigandPNGBDBM50226128(CHEMBL2093893)
Affinity DataKi:  0.205nMAssay Description:Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50226129(CHEMBL1314450)
Affinity DataKi:  0.499nMAssay Description:Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50101815(CHEBI:7550 | Nicardipine)
Affinity DataKi:  0.840nMAssay Description:Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50226130(CHEMBL558616)
Affinity DataKi:  3.10nMAssay Description:Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50101817(Adalat | Adalat Cc | Afeditab Cr | BAY-A-1040 | CH...)
Affinity DataKi:  4.70nMAssay Description:Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50226131(CHEMBL1598680)
Affinity DataKi:  7.10nMAssay Description:Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50226127(CHEMBL542169)
Affinity DataKi:  14nMAssay Description:Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50226126(CHEMBL553553)
Affinity DataKi:  50nMAssay Description:Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-5/beta-6/beta-8(Homo sapiens (Human))
Scifluor Life Sciences

US Patent
LigandPNGBDBM297773(US10118929, Compound A1)
Affinity DataIC50:  0.130nMAssay Description:The optimized protocol was validated by employing reference compounds such as Cilengitide (+Vβ3/αVβ5−VN interaction) and CWHM12 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606867(US11685738, Compound A3)
Affinity DataIC50:  0.570nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Pseudomonas aeruginosa)
Entasis Therapeutics

Curated by ChEMBL
LigandPNGBDBM50200120(CHEMBL260091 | CHIR-090 | US10875832, Compound ChI...)
Affinity DataIC50: <1nMAssay Description:Displacement of fluorescent ligand from Pseudomonas aeruginosa LpxC measured after 30 mins by fluorescence anisotrophy assayMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606865(US11685738, Compound A4)
Affinity DataIC50:  1.40nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606917(US11685738, Compound A23)
Affinity DataIC50:  4.30nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606955(US11685738, Compound A21-2)
Affinity DataIC50:  4.60nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606865(US11685738, Compound A4)
Affinity DataIC50:  5.69nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606947(US11685738, Compound A15s)
Affinity DataIC50:  5.92nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606954(US11685738, Compound A21 | acid )
Affinity DataIC50:  7.64nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Scifluor Life Sciences

US Patent
LigandPNGBDBM197726(US9216985, 17A)
Affinity DataIC50:  8nMAssay Description:The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3K&d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Scifluor Life Sciences

US Patent
LigandPNGBDBM197718(US9216985, 1A)
Affinity DataIC50:  8nMAssay Description:The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3K&d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606883(US11685738, Compound A6)
Affinity DataIC50:  8.25nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606864(US11685738, Compound A1)
Affinity DataIC50:  8.30nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606866(US11685738, Compound A2)
Affinity DataIC50:  9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Scifluor Life Sciences

US Patent
LigandPNGBDBM197724(US9216985, 15A)
Affinity DataIC50:  9nMAssay Description:The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3K&d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606947(US11685738, Compound A15s)
Affinity DataIC50:  9.28nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM50134778((S)-3-(6-Methoxy-pyridin-3-yl)-3-{2-oxo-3-[3-(5,6,...)
Affinity DataIC50:  9.57nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606881(US11685738, Compound A5)
Affinity DataIC50:  9.97nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Scifluor Life Sciences

US Patent
LigandPNGBDBM197728(US9216985, 20A)
Affinity DataIC50:  10nMAssay Description:The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3K&d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606866(US11685738, Compound A2)
Affinity DataIC50:  11.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606884(US11685738, Compound A7)
Affinity DataIC50:  11.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606864(US11685738, Compound A1)
Affinity DataIC50:  13.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Pharmadesign

Curated by ChEMBL
LigandPNGBDBM50334268(CHEMBL1642655 | CHEMBL2205637 | N-(6-(1H-imidazol-...)
Affinity DataIC50:  14nMAssay Description:Inhibition of ASK1 assessed as phosphorylated fluorescent peptide by mobility shift assayMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606917(US11685738, Compound A23)
Affinity DataIC50:  14.8nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Pharmadesign

Curated by ChEMBL
LigandPNGBDBM50334269(4-tert-butyl-N-(imidazo[1,2-a]quinolin-2-yl)benzam...)
Affinity DataIC50:  15nMAssay Description:Inhibition of ASK1 assessed as phosphorylated fluorescent peptide by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606919(US11685738, Compound A28 | acid )
Affinity DataIC50:  16.9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606918(US11685738, Compound A24 | acid )
Affinity DataIC50:  17.5nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM50134778((S)-3-(6-Methoxy-pyridin-3-yl)-3-{2-oxo-3-[3-(5,6,...)
Affinity DataIC50:  17.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606867(US11685738, Compound A3)
Affinity DataIC50:  18.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Pharmadesign

Curated by ChEMBL
LigandPNGBDBM50334270(2-methyl-2-(4-(6-(thiophen-3-yl)imidazo[1,2-a]pyri...)
Affinity DataIC50:  19nMAssay Description:Inhibition of ASK1 assessed as phosphorylated fluorescent peptide by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Scifluor Life Sciences

US Patent
LigandPNGBDBM197720(US9216985, 6A)
Affinity DataIC50:  20nMAssay Description:The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3K&d...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Scifluor Life Sciences

US Patent
LigandPNGBDBM197722(US9216985, 10A)
Affinity DataIC50:  20nMAssay Description:The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3K&d...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606865(US11685738, Compound A4)
Affinity DataIC50:  21.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606883(US11685738, Compound A6)
Affinity DataIC50:  24nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606919(US11685738, Compound A28 | acid )
Affinity DataIC50:  34.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606918(US11685738, Compound A24 | acid )
Affinity DataIC50:  35.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Pseudomonas aeruginosa)
Entasis Therapeutics

Curated by ChEMBL
LigandPNGBDBM50554708(CHEMBL4746493)
Affinity DataIC50:  37nMAssay Description:Displacement of fluorescent ligand from Pseudomonas aeruginosa LpxC measured after 30 mins by fluorescence anisotrophy assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Pseudomonas aeruginosa)
Entasis Therapeutics

Curated by ChEMBL
LigandPNGBDBM50554707(CHEMBL4751248)
Affinity DataIC50:  44nMAssay Description:Displacement of fluorescent ligand from Pseudomonas aeruginosa LpxC measured after 30 mins by fluorescence anisotrophy assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Pseudomonas aeruginosa)
Entasis Therapeutics

Curated by ChEMBL
LigandPNGBDBM50554702(CHEMBL4776055)
Affinity DataIC50:  45nMAssay Description:Displacement of fluorescent ligand from Pseudomonas aeruginosa LpxC measured after 30 mins by fluorescence anisotrophy assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Scifluor Life Sciences

US Patent
LigandPNGBDBM197721(US9216985, 7A)
Affinity DataIC50:  50nMAssay Description:The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3K&d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606955(US11685738, Compound A21-2)
Affinity DataIC50:  50.3nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5/beta-8(Homo sapiens (Human))
Scifluor Life Sciences

US Patent
LigandPNGBDBM297773(US10118929, Compound A1)
Affinity DataIC50:  50.4nMAssay Description:The optimized protocol was validated by employing reference compounds such as Cilengitide (+Vβ3/αVβ5−VN interaction) and CWHM12 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 313 total ) | Next | Last >>
Jump to: